simufilam
Jump to navigation
Jump to search
Indications
- investigational agent for treatment of mild-to-moderate Alzheimer's disease
Dosage
Mechanism of action
- restores altered filamin A
Clinical trials
- NIH-funded phase 2 trial:[1]
- improvement of 10% in ADAS-Cog score after 6 months
- improvement of 29% in Neuropsychiatric Inventory after 6 months[1]
More general terms
References
- ↑ 1.0 1.1 1.2 Hoffman M Simufilam Shows Promise Improving Cognition, Behavior in Alzheimer Disease Patients. Doximity: HCPLive. Feb 5, 2021 https://www.hcplive.com/view/simufilam-shows-promise-improving-cognition-behavior-alzheimer-disease-patients
- ↑ Mandavilli A Scientists Question Data Behind and Experimental Alzheimer's Drug. New York Times. April 18, 2022 https://www.nytimes.com/2022/04/18/health/alzheimers-cassava-simufilam.html